Last checked at 13 May 2019 10:50
Creo Medical Group plc
("Creo" or "the Company")
Posting of Annual Reports and Accounts
Notice of Annual General Meeting
Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that its Report and Accounts for the 18 month period ended 31 December 2018, together with its Notice of Annual General Meeting ("AGM") and a Form of Proxy, will be mailed out to shareholders today.
These documents are available on the Company's website:
http://investors.creomedical.com/investors/reports-and-presentations/2019
The AGM will be held at 10 a.m. on Thursday 6 June 2019 at the Company's registered office, Creo House, Unit 2, Beaufort Park, Beaufort Park Way, Chepstow, Wales NP16 5UH.
Creo Medical Group plc |
|
Richard Rees (CFO) | +44 (0)129 160 6005 |
|
|
Cenkos Securities | +44 (0)20 7397 8900 |
Stephen Keys / Mark Connelly (NOMAD) |
|
Michael Johnson / Russell Kerr (Sales) |
|
|
|
Walbrook PR Ltd | Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com |
Paul McManus | Mob: +44 (0)7980 541 893 |
Helen Cresswell | Mob: +44 (0)7841 917 679 |
About Creo Medical
Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. Creo's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar radio frequency energy (for precise localised cutting) and microwave energy (for controlled coagulation). This technology provides clinicians with flexible, accurate and controlled surgical solutions.
Creo's strategy is to bring its CROMA Advanced Energy platform to market through a suite of medical devices which Creo has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. Creo intends to further develop the CROMA Advanced Energy platform for use on flexible and rigid endoscopic platforms for precise resection, dissection, haemostasis and ablation. Creo believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option of treatment.
For more information about Creo Medical please see our website, investors.creomedical.com